Eloxx Pharmaceuticals, Inc. focuses on developing precision medicines for rare kidney diseases. The company is engaged in the research and development of therapies that target genetic mutations associated with these conditions. Eloxx operates primarily in the biopharmaceutical sector, generating revenue through the advancement of its drug candidates through clinical trials and regulatory approval processes. Its customer base includes healthcare providers and patients affected by rare diseases, with operations primarily in the United States.
